Literature DB >> 1889260

Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes.

M L Brantly1, J T Wittes, C F Vogelmeier, R C Hubbard, G A Fells, R G Crystal.   

Abstract

Diagnosis of the hereditary disorder alpha 1-antitrypsin (alpha 1AT) deficiency is critically dependent on quantification of serum levels of alpha 1AT, a 52-kDa antiprotease that serves to protect the lung from destruction by neutrophil elastase. Although the measurement of serum alpha 1AT levels is not difficult, there is no international standard for alpha 1AT, and investigators in the field recognize that widely used commercially available standards vary by as much as 50 percent. To establish accurate ranges for the common normal and deficient alpha 1AT phenotypes, the present study uses a purified alpha 1AT standard to quantify the alpha 1AT serum levels of 443 individuals with common normal and deficient alpha 1AT phenotypes, including MM, ZZ, SS, MZ, MS, and SZ. Based on the observed values, a statistical model was developed to generate predicted frequency distributions of alpha 1AT serum levels for each of these phenotypes. Based on these studies, the ranges (5th to 95th percentile) for alpha 1AT serum levels of the common phenotypes are: MM, 20 to 53 mumol/L; SS, 20 to 48 mumol/L; ZZ, 3.4 to 7.0 mumol/L; MZ, 15 to 42 mumol/L; MS, 18 to 52 mumol/L; and SZ, 10 to 23 mumol/L. This alpha 1AT standard and these ranges are being used for the National alpha 1-Antitrypsin Deficiency Registry organized under the auspices of the National Heart, Lung, and Blood Institute.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1889260     DOI: 10.1378/chest.100.3.703

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  46 in total

Review 1.  Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease.

Authors:  Sarah K Brode; Simon C Ling; Kenneth R Chapman
Journal:  CMAJ       Date:  2012-07-03       Impact factor: 8.262

2.  Control of inflammation with alpha1-antitrypsin: a potential treatment for islet transplantation and new-onset type 1 diabetes.

Authors:  Gordon C Weir; Maria Koulamnda
Journal:  Curr Diab Rep       Date:  2009-04       Impact factor: 4.810

Review 3.  Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease?

Authors:  Diana Crossley; Robert Stockley; Elizabeth Sapey
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

4.  α-1 Antitrypsin Enhances Islet Engraftment by Suppression of Instant Blood-Mediated Inflammatory Reaction.

Authors:  Jingjing Wang; Zhen Sun; Wenyu Gou; David B Adams; Wanxing Cui; Katherine A Morgan; Charlie Strange; Hongjun Wang
Journal:  Diabetes       Date:  2017-01-09       Impact factor: 9.461

5.  α₁-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts.

Authors:  Inga-Cecilie Sørheim; Per Bakke; Amund Gulsvik; Sreekumar G Pillai; Ane Johannessen; Per I Gaarder; Edward J Campbell; Alvar Agustí; Peter M A Calverley; Claudio F Donner; Barry J Make; Stephen I Rennard; Jørgen Vestbo; Emiel F M Wouters; Peter D Paré; Robert D Levy; Harvey O Coxson; David A Lomas; Craig P Hersh; Edwin K Silverman
Journal:  Chest       Date:  2010-07-01       Impact factor: 9.410

6.  Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method.

Authors:  Jeffrey D Chulay; Guo-Jie Ye; Darby L Thomas; David R Knop; Janet M Benson; Julie A Hutt; Gensheng Wang; Margaret Humphries; Terence R Flotte
Journal:  Hum Gene Ther       Date:  2010-12-12       Impact factor: 5.695

7.  Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors.

Authors:  S Song; M Morgan; T Ellis; A Poirier; K Chesnut; J Wang; M Brantly; N Muzyczka; B J Byrne; M Atkinson; T R Flotte
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

8.  Extensive posttranscriptional deletion of the coding sequences for part of nucleotide-binding fold 1 in respiratory epithelial mRNA transcripts of the cystic fibrosis transmembrane conductance regulator gene is not associated with the clinical manifestations of cystic fibrosis.

Authors:  C S Chu; B C Trapnell; S M Curristin; G R Cutting; R G Crystal
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

9.  Serum levels of alpha1-antitrypsin predict phenotypic expression of the alpha1-antitrypsin gene.

Authors:  Steven J Steiner; Sandeep K Gupta; Joseph M Croffie; Joseph F Fitzgerald
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

10.  Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy.

Authors:  Mark L Brantly; Jeffrey D Chulay; Lili Wang; Christian Mueller; Margaret Humphries; L Terry Spencer; Farshid Rouhani; Thomas J Conlon; Roberto Calcedo; Michael R Betts; Carolyn Spencer; Barry J Byrne; James M Wilson; Terence R Flotte
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.